Olive Leaf Extracts in the Control of Hypertension
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.
Also called NCT05636826
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT05636826
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Tunisia
- Registry status
- Completed
Technical summary
Registry record NCT05636826. Randomized; single masking; primary purpose treatment. Start 2023-12-30 (actual); primary completion 2024-11-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Olive Leaf Extracts in the Control of Hypertension
- Acronym
- Atherolive
- Condition
- Hypertension
- Intervention (Drug)
- atherolive-drug
- Intervention (Drug)
- Placebo Atherolive
- Lead sponsor
- University of Monastir
Record details
- Record id
cardio:ct-nct05636826- Content hash
9e72504b8714764a75d528706fb798a7243b096e3ad7868c61b01f3e4ddc1749